文献速递类风湿关节炎

类风湿关节炎患者中糖皮质激素相关不良事件的发生率与风险

Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-01-01

基于英国临床实践研究数据链,将新发类风湿关节炎患者与同规模年龄性别匹配的非类风湿关节炎人群比较,队列分析估计糖皮质激素相关严重不良事件的发生率与发生率比;在类风湿关节炎患者中行巢式病例对照分析,评估累积剂量和平均日剂量增加对不良事件风险的影响。

要点

  • 类风湿关节炎患者除青光眼外所有研究的不良事件发生率均高于非类风湿关节炎人群。
  • 使用糖皮质激素者的发生率比高于未使用者。
  • 类风湿关节炎患者中,糖皮质激素与糖尿病、骨质疏松、血栓性卒中或心肌梗死、严重感染和死亡风险升高相关。

核心结论

  • 类风湿关节炎患者糖皮质激素相关不良事件发生率升高,累积剂量和平均日剂量增加与发生不良事件的风险增加相关。

研究设计与样本

  • 使用英国临床实践研究数据链,将新发类风湿关节炎患者与等样本量、按年龄和性别匹配的非类风湿关节炎对照人群比较。
  • 队列分析按糖皮质激素使用分层估计糖皮质激素相关不良事件的发生率和发生率比。
  • 在类风湿关节炎患者中开展系列巢式病例对照分析,评估累积剂量和平均日剂量增加的影响,病例按年龄、性别和全科诊所与对照匹配。

主要发现

  • 类风湿关节炎患者除青光眼外所有研究不良事件的发生率均高于非类风湿关节炎患者。
  • 使用糖皮质激素者的发生率比高于未使用者。
  • 类风湿关节炎患者中,糖皮质激素与糖尿病风险升高相关(调整OR 1.33,95%CI 1.14-1.56)。
  • 类风湿关节炎患者中,糖皮质激素与骨质疏松风险升高相关(调整OR 1.41,95%CI 1.25-1.59)。
  • 类风湿关节炎患者中,糖皮质激素与血栓性卒中或心肌梗死风险升高相关(调整OR 1.28,95%CI 1.07-1.52)、严重感染风险升高相关(调整OR 1.28,95%CI 1.11-1.48)和死亡风险升高相关(调整OR 1.33,95%CI 1.19-1.48)。

关键数值与推荐

  • 除青光眼、高血压和胃肠穿孔或出血外,所有结局均随累积剂量和平均日剂量增加呈风险增加趋势(P < 0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using the UK Clinical Practice Research Datalink, we examined the incidence of glucocorticoid (GC)-related serious adverse events (SAEs) in rheumatoid arthritis (RA) and non-RA patients and quantified the risk of SAEs in patients with RA. METHODS: We matched incident patients with RA to an age- and sex-matched, non-RA comparison group of equal size. In a cohort analysis, we estimated incidence rates (IRs) and IR ratios (IRRs) for GC-related AEs (i.e., diabetes mellitus [DM], osteoporosis, fractures, glaucoma, hypertension, gastrointestinal [GI] perforation or bleeding, thrombotic stroke or myocardial infarction [MI], or death), stratified by GC use. We conducted a series of nested case-control analyses among patients with RA, evaluating the effects of increasing cumulative and average daily GC dose. Cases of each outcome were matched to controls for age, sex, and general practice. We calculated adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) for each outcome. RESULTS: Patients with RA had a higher incidence for all investigated SAEs except glaucoma, compared to non-RA patients. IRRs were greater in those patients prescribed a GC than in those without. In patients with RA, GCs were associated with an elevated risk of DM (adjusted OR 1.33 [95% CI 1.14-1.56]), osteoporosis (adjusted OR 1.41 [95% CI 1.25-1.59]), thrombotic stroke or MI (adjusted OR 1.28 [95% CI 1.07-1.52]), serious infection (adjusted OR 1.28 [95% CI 1.11-1.48]), and death (adjusted OR 1.33 [95% CI 1.19-1.48]). There was a trend of increasing risk with increasing cumulative and average daily GC dose for all outcomes other than glaucoma, hypertension, and GI perforations or bleeding (P < 0.05). CONCLUSION: Patients with RA had an increased incidence of GC-related AEs. Increasing cumulative and average daily GC doses were found to be associated with an increasing risk of developing an AE.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wilson JC, Sarsour K, Gale S, et al. Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2019. PMID: 29856128. doi:10.1002/acr.23611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。